Evidence map›Paper›PMID 26023566›Full record

ArticleJournal of clinical and diagnostic research : JCDR2015

To study the efficacy and safety of doxophylline and theophylline in bronchial asthma.

Sami Manzoor Margay, Samina Farhat, Sharanjit Kaur, Hilal Ahmad Teli

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and diagnostic research : JCDR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03879590 (Efficacy Of Doxophylline As A Sparing Treatment For Inhaled Corticosteroids In Mexican Children With Asthma), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03879590 phase3unknown statusnot on this mapstarted 2019, after this paper: background citation

Efficacy Of Doxophylline As A Sparing Treatment For Inhaled Corticosteroids In Mexican Children With Asthma

TypeinterventionalSponsorUniversidad Autonoma de Nuevo LeonRan2019 to 2019Enrolled60ConditionsAsthma Chronic, Asthma in ChildrenArmsDoxophylline, Budesonide
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. The role of CAT in evaluating the response to treatment of patients with AECOPD.International journal of chronic obstructive pulmonary disease · 2018
    Article
  6. Doxofylline is not just another theophylline!International journal of chronic obstructive pulmonary disease · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sami Manzoor MargayAssistant Professor, Department of Pharmacology, Maharishi Markandeshwar Medical College and Hospital , Kumarhatti, Solan, (H.P), India .
Samina FarhatAssociate Professor, Department of Pharmacology, GMC , Srinagar, India .
Sharanjit KaurAssociate Professor, Department of Pharmacology, Maharishi Markandeshwar Medical College and Hospital , Kumarhatti, Solan, (H.P), India .
Hilal Ahmad TeliAssistant Professor, Department of Medicine, Maharishi Markandeshwar Medical College and Hospital , Kumarhatti, Solan, (H.P), India .
Maharishi Markandeshwar University, Mullana · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAsthma is a non communicable chronic disease prevalent all over the world. Two commonly used methylxanthines, theophylline and doxofylline were compared in the study in stable asthmatic patients at recommended doses by various spirometric lung function tests with forced expiratory volume at second one (FEVI) between 50 to 80% of predicted FEVI. MATERIALS AND

methodsA total of 100 patients were divided in two groups. Group I was administered 300 mg theophylline twice a day and Group II was administered doxofylline 400 mg twice a day orally for six weeks. Spirometric variables symptom score, and adverse effects were recorded at the baseline level and after six weeks of therapy. Data was compared and analysed statistically.

resultsThe spirometric values of forced expiratory volume in 1 second (FEVI), forced vital capacity (FVC), and FEV1/FVC showed a statistically significant improvement over base line with the use of both theophylline as well as doxophylline, but were not statistically different from each other. There was a statistically significant improvement in peak expiratory flow rate (PEFR) after six weeks of treatment with doxophylline compared to theophylline. It was found that the doxophylline has a better safety profile as compared to theophylline. Adverse events occurred in a greater proportion of patients in the theophylline group.

conclusionIn the study it was concluded that both theophylline and doxofylline improved the lung function tests and symptoms in patients of mild Bronchial Asthma, but doxofylline has a better profile in terms of safety.

Indexed as

Lung function testsMethylxanthinesModerate asthma

Identifiers

PMID26023566
PMCPMC4437080
OpenAlexW2182605043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.